AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

Observational Usage Study of Statins in Primary Care in France

Completed

Conditions: Healthy

First Posted Date: 2008-05-19

Last Posted Date: 2010-12-02

Lead Sponsor: AstraZeneca

Target Recruit Count: 2100

Registration Number: NCT00680082

Locations: 🇨🇳
Research Site, Wenzhou, Zhejiang, China

Observational Usage and Efficacy Study of Candesartan in Heart Failure Treatment in France

Completed

Conditions: Heart Failure
Cohort Study

Interventions: Drug: Candesartan

First Posted Date: 2008-05-19

Last Posted Date: 2010-12-02

Lead Sponsor: AstraZeneca

Target Recruit Count: 450

Registration Number: NCT00679640

Locations: 🇫🇷
Research Site, Maisons Laffitte, Yvelines, France

Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: exenatide once weekly
Drug: metformin
Drug: sitagliptin
Drug: pioglitazone

First Posted Date: 2008-05-13

Last Posted Date: 2015-04-09

Lead Sponsor: AstraZeneca

Target Recruit Count: 820

Registration Number: NCT00676338

Locations: 🇬🇧
Research Site, Swansea, United Kingdom
🇮🇱
Research SIte, Tel-Hashomer, Israel

Drug-Drug Interaction Study of Esomeprazole (D961H) Capsule and Loxoprofen Tablet After Repeated Oral Administration in Japanese Males

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Esomeprazole (D961H)
Drug: Loxoprofen

First Posted Date: 2008-05-12

Last Posted Date: 2009-03-12

Lead Sponsor: AstraZeneca

Target Recruit Count: 30

Registration Number: NCT00676117

Locations: 🇯🇵
Research Site, Osaka-city, Osaka, Japan

Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin

Phase 3

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Dapagliflozin
Drug: Placebo

First Posted Date: 2008-05-07

Last Posted Date: 2013-10-29

Lead Sponsor: AstraZeneca

Target Recruit Count: 1240

Registration Number: NCT00673231

Locations: 🇬🇧
Research Site, Swansea, United Kingdom

(Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer

Phase 3

Completed

Conditions: Non-Metastatic Prostate Cancer

Interventions: Drug: Placebo
Drug: Bicalutamide

First Posted Date: 2008-05-07

Last Posted Date: 2010-12-10

Lead Sponsor: AstraZeneca

Target Recruit Count: 3588

Registration Number: NCT00673205

Locations: 🇬🇧
Research Site, Shrewsbury, United Kingdom

Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects

Phase 2

Completed

Conditions: Overweight
Obesity

Interventions: Drug: pramlintide acetate
Drug: placebo-P
Drug: placebo-M
Drug: metreleptin

First Posted Date: 2008-05-07

Last Posted Date: 2015-04-15

Lead Sponsor: AstraZeneca

Target Recruit Count: 636

Registration Number: NCT00673387

Locations: 🇺🇸
Research Site, Olympia, Washington, United States

Quetiapine Fumarate (Seroquel) as Mono-Therapy or Adjunct to Lithium in the Treatment of Patients With Acute Mania in Bipolar Disorder

Phase 4

Completed

Conditions: Acute Mania in Bipolar Disorder

Interventions: Drug: Quetiapine Fumarate
Drug: Lithium

First Posted Date: 2008-05-06

Last Posted Date: 2012-07-12

Lead Sponsor: AstraZeneca

Target Recruit Count: 376

Registration Number: NCT00672490

Locations: 🇨🇳
Research Site, Huzhou, Zhejiang, China

Casodex vs Placebo in Non-Metastatic Early Prostate Cancer

Phase 3

Completed

Conditions: Non-Metastatic Prostate Cancer

Interventions: Drug: Placebo
Drug: Bicalutamide

First Posted Date: 2008-05-06

Last Posted Date: 2009-05-27

Lead Sponsor: AstraZeneca

Target Recruit Count: 1218

Registration Number: NCT00672282

Locations: 🇸🇪
Research Site, Vostervik, Sweden

Pharmacokinetics, Safety & Tolerability of ZD4054 (Zibotentan) in Subjects With Normal, Mild, Moderate and Severe Hepatic Impairment

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: ZD4054

First Posted Date: 2008-05-06

Last Posted Date: 2010-09-28

Lead Sponsor: AstraZeneca

Target Recruit Count: 32

Registration Number: NCT00672581

Locations: 🇨🇿
Research Site, Praha 6, Czech Republic

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy